Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ADHD management during the COVID-19 pandemic: guidance from the European ADHD Guidelines Group.
Cortese S, Asherson P, Sonuga-Barke E, Banaschewski T, Brandeis D, Buitelaar J, Coghill D, Daley D, Danckaerts M, Dittmann RW, Doepfner M, Ferrin M, Hollis C, Holtmann M, Konofal E, Lecendreux M, Santosh P, Rothenberger A, Soutullo C, Steinhausen HC, Taylor E, Van der Oord S, Wong I, Zuddas A, Simonoff E; European ADHD Guidelines Group. Cortese S, et al. Among authors: soutullo c. Lancet Child Adolesc Health. 2020 Jun;4(6):412-414. doi: 10.1016/S2352-4642(20)30110-3. Epub 2020 Apr 17. Lancet Child Adolesc Health. 2020. PMID: 32311314 Free PMC article. No abstract available.
A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD.
Buitelaar JK, Danckaerts M, Gillberg C, Zuddas A, Becker K, Bouvard M, Fagan J, Gadoros J, Harpin V, Hazell P, Johnson M, Lerman-Sagie T, Soutullo CA, Wolanczyk T, Zeiner P, Fouche DS, Krikke-Workel J, Zhang S, Michelson D; Stomoxetine International Study Group. Buitelaar JK, et al. Among authors: soutullo ca. Eur Child Adolesc Psychiatry. 2004 Aug;13(4):249-57. doi: 10.1007/s00787-004-0401-3. Eur Child Adolesc Psychiatry. 2004. PMID: 15365896 Clinical Trial.
European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Lyne A, Squires L. Coghill D, et al. Among authors: soutullo c. Eur Neuropsychopharmacol. 2013 Oct;23(10):1208-18. doi: 10.1016/j.euroneuro.2012.11.012. Epub 2013 Jan 15. Eur Neuropsychopharmacol. 2013. PMID: 23332456 Free article. Clinical Trial.
A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.
Soutullo C, Banaschewski T, Lecendreux M, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Bloomfield R, Squires LA, Coghill DR. Soutullo C, et al. CNS Drugs. 2013 Sep;27(9):743-51. doi: 10.1007/s40263-013-0086-6. CNS Drugs. 2013. PMID: 23801529 Free PMC article. Clinical Trial.
Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder.
Banaschewski T, Soutullo C, Lecendreux M, Johnson M, Zuddas A, Hodgkins P, Adeyi B, Squires LA, Coghill D. Banaschewski T, et al. Among authors: soutullo c. CNS Drugs. 2013 Oct;27(10):829-40. doi: 10.1007/s40263-013-0095-5. CNS Drugs. 2013. PMID: 23893527 Free PMC article. Clinical Trial.
Post hoc analyses of the impact of previous medication on the efficacy of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in a randomized, controlled trial.
Coghill DR, Banaschewski T, Lecendreux M, Soutullo C, Zuddas A, Adeyi B, Sorooshian S. Coghill DR, et al. Among authors: soutullo c. Neuropsychiatr Dis Treat. 2014 Oct 29;10:2039-47. doi: 10.2147/NDT.S68273. eCollection 2014. Neuropsychiatr Dis Treat. 2014. PMID: 25378930 Free PMC article.
Cognitive training for attention-deficit/hyperactivity disorder: meta-analysis of clinical and neuropsychological outcomes from randomized controlled trials.
Cortese S, Ferrin M, Brandeis D, Buitelaar J, Daley D, Dittmann RW, Holtmann M, Santosh P, Stevenson J, Stringaris A, Zuddas A, Sonuga-Barke EJ; European ADHD Guidelines Group (EAGG). Cortese S, et al. J Am Acad Child Adolesc Psychiatry. 2015 Mar;54(3):164-74. doi: 10.1016/j.jaac.2014.12.010. Epub 2014 Dec 29. J Am Acad Child Adolesc Psychiatry. 2015. PMID: 25721181 Free PMC article. Review.
Differences in maintenance of response upon discontinuation across medication treatments in attention-deficit/hyperactivity disorder.
Buitelaar J, Asherson P, Soutullo C, Colla M, Adams DH, Tanaka Y, Haynes VS, Escobar R, Upadhyaya H. Buitelaar J, et al. Among authors: soutullo c. Eur Neuropsychopharmacol. 2015 Oct;25(10):1611-21. doi: 10.1016/j.euroneuro.2015.06.003. Epub 2015 Jun 22. Eur Neuropsychopharmacol. 2015. PMID: 26169574 Free article. Review.
Neurofeedback for Attention-Deficit/Hyperactivity Disorder: Meta-Analysis of Clinical and Neuropsychological Outcomes From Randomized Controlled Trials.
Cortese S, Ferrin M, Brandeis D, Holtmann M, Aggensteiner P, Daley D, Santosh P, Simonoff E, Stevenson J, Stringaris A, Sonuga-Barke EJ; European ADHD Guidelines Group (EAGG). Cortese S, et al. J Am Acad Child Adolesc Psychiatry. 2016 Jun;55(6):444-55. doi: 10.1016/j.jaac.2016.03.007. Epub 2016 Apr 1. J Am Acad Child Adolesc Psychiatry. 2016. PMID: 27238063 Review.
108 results